Monday, September 21, 2009
Although kinase inhibitors are becoming first- or second-line
therapies for many cancers, issues with toxicity and serious adverse events
remain. Xcovery Inc. believes its medicinal chemistry approach can generate kinase
inhibitors with lower toxicity and larger therapeutic windows than existing
The company hopes to have up to
three molecules in the clinic by the end of next year.